This HTML5 document contains 56 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n11http://linked.opendata.cz/ontology/domain/vavai/riv/statVydaniPatentuVzoru/
dctermshttp://purl.org/dc/terms/
n13http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n5http://linked.opendata.cz/resource/domain/vavai/projekt/
n23http://linked.opendata.cz/ontology/domain/vavai/riv/uzemniOchranaPatentu/
n21http://linked.opendata.cz/ontology/domain/vavai/
n15http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F61389030%3A_____%2F07%3A00090753%21RIV12-AV0-61389030/
n17http://linked.opendata.cz/resource/domain/vavai/zamer/
n4http://linked.opendata.cz/ontology/domain/vavai/riv/
rdfshttp://www.w3.org/2000/01/rdf-schema#
n16http://linked.opendata.cz/ontology/domain/vavai/riv/vyuzitiPatentuVzoru/
skoshttp://www.w3.org/2004/02/skos/core#
n20http://linked.opendata.cz/ontology/domain/vavai/riv/licencniPoplatek/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n6http://linked.opendata.cz/ontology/domain/vavai/riv/vyuzitiJinymSubjektem/
n10http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n19http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n7http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n22http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n18http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n14http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F61389030%3A_____%2F07%3A00090753%21RIV12-AV0-61389030
rdf:type
skos:Concept n21:Vysledek
rdfs:seeAlso
http://rustreg.upol.cz/patents/06_heterocycl_comp/udelene_patenty/NZ_538597.pdf
dcterms:description
Disclosed is a pharmaceutical composition which contains a heterocyclic compound based on N6-substituted adenine of the general formula I wherein: R2 is a H, halogen, hydroxyl, alkoxy, amino, hydrazo, mercapto, carboxyl, cyano, nitro, amido, sulfo, sulfamido, acylamino, acyloxy, alkylamino, dialkylamino, alkylmercapto, cycloalkyl or carbamoyl group; R6 is R6'-X; X is -NH- R6' is substituted phenyl or substituted benzyl. The disclosed composition is for use as a mitotic or antimitotic compound expecially for treating cancer, psoriasis, rheumatoid arthritis, lupus, type I diabetes, multiple sclerosis, restenosis, polycystic kidney disease, graft rejection, graft versus host disease, gout, parasitoses and Alzheimers disease among others. Disclosed is a pharmaceutical composition which contains a heterocyclic compound based on N6-substituted adenine of the general formula I wherein: R2 is a H, halogen, hydroxyl, alkoxy, amino, hydrazo, mercapto, carboxyl, cyano, nitro, amido, sulfo, sulfamido, acylamino, acyloxy, alkylamino, dialkylamino, alkylmercapto, cycloalkyl or carbamoyl group; R6 is R6'-X; X is -NH- R6' is substituted phenyl or substituted benzyl. The disclosed composition is for use as a mitotic or antimitotic compound expecially for treating cancer, psoriasis, rheumatoid arthritis, lupus, type I diabetes, multiple sclerosis, restenosis, polycystic kidney disease, graft rejection, graft versus host disease, gout, parasitoses and Alzheimers disease among others.
dcterms:title
Heterocyclic compound based on N6-substituted adenine, methods of their preparation, their use for preparation of drugs and pharmaceutical preparations containing these compounds Heterocyclic compound based on N6-substituted adenine, methods of their preparation, their use for preparation of drugs and pharmaceutical preparations containing these compounds
skos:prefLabel
Heterocyclic compound based on N6-substituted adenine, methods of their preparation, their use for preparation of drugs and pharmaceutical preparations containing these compounds Heterocyclic compound based on N6-substituted adenine, methods of their preparation, their use for preparation of drugs and pharmaceutical preparations containing these compounds
skos:notation
RIV/61389030:_____/07:00090753!RIV12-AV0-61389030
n4:aktivita
n7:Z n7:P
n4:aktivity
P(GA206/07/0570), P(GA522/06/0108), Z(AV0Z50380511)
n4:cisloPatentuVzoru
NZ538597
n4:datumUdeleniPatentuVzoru
2007-01-11+01:00
n4:dodaniDat
n14:2012
n4:domaciTvurceVysledku
n13:4012240 n13:5991803 n13:4712048 n13:8905428 n13:9579982 n13:9896821
n4:druhVysledku
n18:P
n4:duvernostUdaju
n10:S
n4:entitaPredkladatele
n15:predkladatel
n4:idSjednocenehoVysledku
424025
n4:idVysledku
RIV/61389030:_____/07:00090753
n4:jazykVysledku
n19:eng
n4:klicovaSlova
adenine; cytokinins; cytotoxicity
n4:klicoveSlovo
n9:cytotoxicity n9:cytokinins n9:adenine
n4:kontrolniKodProRIV
[93F74C85A90A]
n4:licencniPoplatek
n20:N
n4:mistoVydaniPatentuVzoru
Wellington
n4:nazevVydavatelePatentuVzoru
Intellectual Property Office of New Zealand (IPONZ)
n4:obor
n22:ED
n4:pocetDomacichTvurcuVysledku
6
n4:pocetTvurcuVysledku
7
n4:projekt
n5:GA522%2F06%2F0108 n5:GA206%2F07%2F0570
n4:rokUplatneniVysledku
n14:2007
n4:statVydaniPatentuVzoru
n11:NZ
n4:tvurceVysledku
Lenobel, René Strnad, Miroslav Zatloukal, Marek Doležal, Karel Werbrouck, S. Popa, Igor Holub, Jan
n4:uzemniOchranaPatentu
n23:D
n4:vlastnik
n15:vlastnikVysledku
n4:vyuzitiJinymSubjektem
n6:A
n4:vyuzitiPatentuVzoru
n16:B
n4:zamer
n17:AV0Z50380511
n4:vlastnikPatentuVzoru
Ústav experimentální botaniky AVČR, v. v. i.